Bayer’s Kerendia was first approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes in 2021.

Pitchbook’s look back at the first 6 months of 2025 and projects on the second half of the year.

This is an interesting look at how some small changes can help you sound confident and help you gain respect.

GE HealthCare’s Vizamyl, which was first approved by the FDA in 2013, has been approved to expanded uses that enable more objective scans and the ability to track the benefits of new therapies.

According to the Federal Bank of St. Louis, businesses are hiring at one of the slowest rates since 2015.

If you are currently searching for a job, experts recommend tapping into your network as much as possible and celebrating the small wins - even if they’re as small as updating your resume.

Enflonsia, Merck’s medication to treat respiratory syncytial virus (RSV) in infants, has been approved by the FDA. It will now compete with Sanofi and AstraZeneca’s Beyfortus, which was approved by the FDA in July 2023.

No matter your industry, thousands of American workers have been affected by widespread layoffs in 2025.

Stefan Falk, a leadership consultant who studies workplace psychology, has spent more than 30 years helping thousands of individuals and CEOs at multimillion-dollar organizations.

An interesting look at how women can take control of their careers and beat the broken rung - Click here

Life Science Washington has reported that from 2013 to 2023, there has been a 50% job growth. This life sciences cluster has outpaced both national life science growth and private sector growth in Washington.

Sabina Nawas, a former Microsoft HR executive, so many people ‘simply don’t get the basics right.’ Nawas spent 15 years at Microsoft before leaving to start an executive coaching company where she works with senior leaders.

After a patient became ill with a potential drug-induced liver injury, Pfizer announced it would discontinue the development of danuglipron, an orally administered experimental treatment for weight management.

As the workforce rapidly evolves, here is an interesting look at Workforce Trends put together by TI Verbatim Consulting…

People can go to extremes to be taken seriously and earn respect from their peers. Sometimes in doing so they do not sound very smart at all.

LinkedIn has recently posted a Skills on the Rise report showcasing the fastest-growing skills in the US. These skills can help you differentiate yourself among candidates.

Every year there are many prominent exclusivity losses in the pharmaceutical industry but this year’s list has some notable ones.

Number 1 on the list is Johnson & Johnson's Stelara, used to treat Psoriatic arthritis, plaque psoriasis,

This edition of Life Sciences Monthly Pulse from Outcome Capital is packed with in-depth analysis and strategic insights that are shaping the future of the life sciences sector. Their team of experts breaks down the key industry developments you need to know.

In what is described as an ‘always tricky’ Q4, 21 of 22 of the world’s biopharma companies that reported quarterly revenue of at least $2 billion reported an increase in revenue in Q4 of 2024. Leading those increases are Eli Lilly (+45%) and Novo Nordisk (+30%). The only company thus far reporting a decrease is Teva.

GSK’s 5-in-1 meningococcal vaccine, Penmenvy, is designed to protect people ages 10 to 25 against meningococcal serogroups A, B, C, W and Y (MenABCWY), which together cause the most persistent meningococcal disease (IMD) cases globally.

According to a recent survey of 1,824 U.S. adults in white-collar jobs by Harris Poll on behalf of global events company Freeman, 91% of Gen Z workers say they desire a balance between virtual and in-person opportunities. This will allow them to connect with others at their company and in their industry.